SC
EPRX

SummitTX Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

SummitTX Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Sell
318,784
-9,213
-3% -$63.5K 0.05% 326
2026
Q1 		$2.37M Buy
327,997
+152,049
+86% +$1.22M 0.07% 275
2025
Q4 		$1.33M Buy
+175,948
New +$1.08M 0.04% 367

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SummitTX Capital's EPRX Position: Q2 2026 in Review

SummitTX Capital reduced its Eupraxia Pharmaceuticals (EPRX) stake by 2.8% in Q2 2026, selling an estimated $63.5K and leaving 318,784 shares worth $2.11M. The position accounts for 0.05% of the portfolio, ranked #326.

SummitTX Capital first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.37M in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • SummitTX Capital held 318,784 shares of Eupraxia Pharmaceuticals worth $2.11M as of Q2 2026.
  • SummitTX Capital sold 9,213 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $63.5K.
  • Eupraxia Pharmaceuticals made up 0.05% of SummitTX Capital's portfolio in Q2 2026, its #326 holding.
  • SummitTX Capital first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • SummitTX Capital's Eupraxia Pharmaceuticals position peaked at $2.37M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.